Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Company
Company
Our History
Our Team
Careers
Partners
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Patient Access
Medical Affairs
Patient Access
Contact Medical Affairs
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Resources
Resources
In the News
Press Releases
Patient Resources
FAQ
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Investors
Investors
Investor Overview
Financial Information
Events
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Agenus Stakeholder Webcast March 2026 | Access and Execution
Webcast
2026
Webcast
February 7, 2026 5:00 PM
Agenus Stakeholder Webcast January 2026 | Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026
Webcast
2026
Archived Events
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September 21, 2020 3:18 AM
Agenus Discussion with Dr. David O'Malley and William Blair on ESMO Presentation of Balstilimab plus Zalifrelimab in Cervical Cancer
2020
Webcast
September 18, 2020 10:00 AM
ESMO 2020 Presentation of Single-agent Anti-PD-1 Balstilimab or in Combination with Anti-CTLA-4 Zalifrelimab for Recurrent/Metastatic (R/M) Cervical Cancer (CC)
2020
Webcast
September 17, 2020 4:20 PM
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With, Hosted by Jeremy Abbate